ZCZachary Corey

Zachary Corey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zachary Corey has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Molecular Characterization of Sclerosing Nevi With Pseudomelanomatous Features

    by Zachary Corey, Mckinzie Johnson, John Fowler, Joshua Wisell, Dara L. Aisner, Amy Guimaraes‐Young, Shyam S. Raghavan

    Introduction: Sclerosing nevi with pseudomelanomatous features (SNPF) are rare melanocytic lesions characterized by a distinctive trizonal architecture, created by lateral shouldering of the junctional component and nests of melanocytes within the dermis that can histologically mimic melanoma, posing a diagnostic dilemma. Although prior clinicopathologic studies suggest benign behavior, their molecular features have not been characterized. Methods: We retrospectively identified nine SNPFs (2004–2024) and performed detailed histopathologic and immunohistochemical evaluation. Targeted next‐generation sequencing (NGS) with a 498‐gene hybrid capture‐based panel was performed on microdissected, melanocyte‐enriched tissue, with macrodissection used as salvage in low nucleic acid yield cases that initially failed. SNPF results were compared to a comparator group of BRAF ‐mutated melanomas tested on the same assay. Results: Patients ranged from 25 to 65 years (median: 41), with lesions most commonly on the trunk. All cases demonstrated classic trizonal morphology with epidermal flattening, superficial dermal fibroplasia, and deeper dermal nevus nests. Immunohistochemistry showed uniform PRAME negativity and retained mosaic p16 expression. Molecular testing was successful in eight of the nine cases, all of which harbored a BRAF V600E mutation (VAF: 1.3%–27%). No additional pathogenic mutations or copy number alterations were identified. Comparator BRAF ‐mutated melanomas had additional, detectable co‐occurring pathogenic mutations and/or copy number variations in 19 of the 20 cases. Conclusions: SNPFs consistently demonstrate a molecular profile indistinguishable from conventional benign nevi and lack genomic features of melanoma. These findings provide molecular support for the benign nature of SNPF.

  • Open Access

    Pilot Voided Volume Validation Study: Sound-Based Smartphone Applications Can Accurately Measure Voided Volume

    by Zachary Corey, Aisha Rashid, Kreesha Shah, Billal Alamarie, Joseph Y. Clark

    Background/Objectives: The objective of this study was to test the accuracy of two sound-based voided volume measurement applications compared to voided volume based on the measurement of pre- and post-void weight using a high-resolution scale. Methods: Seven male and four female volunteers participated. Male and female volunteers used the proudP and Healthy Bladder-Voiding Diary mobile apps, respectively, to measure sound-based voided volume (SVV). The difference between pre- and post-void weight was calculated and converted to mL to be the true voided volume (TVV) using a high-resolution scale. Pearson correlation coefficients were calculated, and paired t-tests were completed. Results: Eighty-one voids were recorded (42M/39F). The median male participant age was 25 years. Male SVV ranged from 42 to 790 mL, and TVV ranged from 61 to 880 mL. The mean difference was 39 mL (95% CI, 18–59 mL). SVV and TVV comparison revealed a strong correlation (r = 0.977, p < 0.0001). Bland–Altman analysis revealed a mean bias of 39 mL. The median female participant age was 25 years. Female SVV ranged from 32 to 440 mL, and TVV ranged from 20 to 682 mL. The mean difference was 55 mL (95% CI, 23–88 mL). SVV and TVV comparison revealed a correlation (r = 0.882, p < 0.0001). Bland–Altman analysis demonstrated a mean bias of 55 mL. Conclusions: In this pilot study, we found that the male and female apps have a strong correlation to true voided volume (male > female app) and can be used by patients to track voided volume at home. The male app accurately measures voided volume within 60 mL from the TVV; however, the female app is less accurate. These preliminary findings warrant validation in larger prospective cohorts.

  • Open Access

    Pilot Voided Volume Validation Study: Sound-Based Smartphone Applications Can Accurately Measure Voided Volume

    by Zachary Corey, Aisha Rashid, Kreesha Shah, Billal Alamarie, Joseph Y. Clark

    Background/Objectives: To test the accuracy of two sound-based voided volume measurement applications compared to voided volume based on the measurement of pre- and post-void weight using a high-resolution scale. Methods: Seven male and four female volunteers participated. Male and female volunteers used the ProudP and Healthy Bladder-Voiding Diary mobile apps, respectively, to measure sound-based voided volume (SVV). The difference between pre- and post-void weight was calculated and converted to mL to be the true-voided volume (TVV) using a high-resolution scale. A Pearson correlation coefficient and paired t-test were completed. Results: Eighty-two voids were recorded (42M/40F). Median male participant age was 25.9 years. Male SVV ranged from 42-790 mL and TVV ranged from 61-880 mL. Mean difference was 39 mL (95% CI, 18-59 mL). SVV and TVV comparison revealed a strong correlation (r = 0.977, p < 0.0001). Equivalence testing indicated a p-value of 0.022. Median female participant age was 25.0 years. Female SVV ranged from 28-440 mL and TVV ranged from 10-682 mL. Mean difference was 53 mL (95% CI, 22-84 mL). Equivalence testing indicated a p-value of 0.330. SVV and TVV comparison revealed a correlation (r = 0.888, p < 0.0001). Conclusions: The male and female app have a strong correlation to true void volume (male > female app) and can be used by patients to track voided volume at home. The male app accurately measures voided volume within 60 mL from the TVV; however, the female app is less accurate.

  • Spitz Nevi With Novel BRAF Fusions: A Report of Two Cases With Striking Morphologic Features

    by Zachary Corey, Danica Wiredja, Nicholas Do Willard, Joshua Wisell, Shyam S. Raghavan

    Spitz neoplasms comprise a spectrum of melanocytic lesions with overlapping clinical and histologic features. BRAF fusions account for only 5%–6% of Spitz neoplasms with a limited number of fusion partners being characterized. We report 2 Spitz nevi with novel BRAF fusions and reproducible morphologic findings. The first case, a 35-year-old man with a finger mass, morphologically demonstrated intraepidermal and dermal proliferation of enlarged epithelioid melanocytes without maturation, and a striking pattern of neurotropism and angiotropism. Immunohistochemistry revealed AHNAK::BRAF fusion. The second case, a 47-year-old man with an atypical skin lesion on the back of his neck, exhibited a circumscribed intradermal proliferation of epithelioid and spindle melanocytes with Spitzoid cytomorphology, again characterized by the striking pattern of neurotropism and entrapment of epithelioid cells within a fibrous stroma. This lesion was PRAME-negative with retained p16, and molecular studies identified a novel PDE4DIP::BRAF fusion. Both fusions preserved the BRAF kinase domain while eliminating its N-terminal regulatory regions. These cases expand the molecular spectrum of Spitz neoplasms and underscore neurotropism as a potential morphologic clue for BRAF fusion-driven Spitz nevi.

  • Developing a Protocol for Therapeutic Plasma Exchange in Tandem With Continuous Renal Replacement Therapy (CRRT) and ExtraCorporeal Membrane Oxygenation (ECMO) in Pediatric Patients

    by Cyril Jacquot, Maria Di Mola, Reuben Jacob, Gagan Mathur, Cheryl Pacheco, Angelica Vivero, Zachary Corey, Ileana Lopez‐Plaza, Kyle Annen

    Therapeutic plasma exchange (TPE) in pediatric patients presents many challenges, including management of a large extracorporeal volume (ECV) and calcium replacement for patients who may not be able to express signs of hypocalcemia or other associated adverse events with a large ECV. Pediatric patients who are critically ill on continuous renal replacement therapy (CRRT) and/or extracorporeal membrane oxygenation (ECMO) may have indications for TPE, such as sepsis or liver failure anticipating transplant. It may be difficult or clinically detrimental to take the patient off the CRRT or ECMO circuit to perform TPE. Connecting the TPE device into the preexisting circuit is feasible with the understanding of the principles of the circuit flow set up and monitoring to mitigate adverse events. Effective communication among clinical teams managing distinct extracorporeal circuits is critical to ensuring coordinated patient care.


  • Open Access

    Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations

    by Karshana J. Kalyanaraman, Zachary Corey, Andre Navarro, Lynn E. Heasley, Raphael A. Nemenoff

    The application of personalized medicine to lung adenocarcinoma has resulted in new therapies based on specific oncogenic drivers that have improved patient outcomes. However, oncogene-defined subsets of patients exhibit a significant heterogeneity of response to these agents. Defining the factors that mediate the varied depth and duration of response are critical to developing new therapeutic strategies. While the examination of patient samples can provide important correlations, definitive mechanistic studies require the use of relevant preclinical models. Based on a large body of data, interactions between cancer cells and the surrounding tumor microenvironment, comprised of inflammatory, immune, and vascular cells, represent a critical determinant of therapeutic response. In this review, we focus on preclinical models that can be used to explore these interactions, identify new therapeutic targets, and test combination therapies. In particular, we will describe the use of implantable orthotopic immunocompetent models employing a panel of murine lung adenocarcinoma cell lines with oncogenic drivers common to human lung adenocarcinoma as a powerful system to develop new treatment approaches.


  • Open Access

    Violaceous Nodules on the Left Forearm of an Immunosuppressed Patient Following Heart Transplantation for Cardiac Amyloidosis

    by Zachary Corey, Lydia A. Luu, Sabrina Newman, Shyam S. Raghavan

    We present the case of a 60-year-old immunocompromised man who presented with two pruritic pink–red indurated nodules with overlying scale and focal areas of ulceration on his left dorsal and left medial forearm, which evolved over a 2-month period. The pathology showed numerous fungal hyphae present that were pauci-septate with various branched angles and variable hyphal thickness. Fungal cultures grew Rhizopus species and a universal fungal PCR detected the Rhizopus oryzae complex. Based on the clinicopathologic correlation, the diagnosis of cutaneous mucormycosis was made. Cutaneous mucormycosis is an aggressive fungal infection of the Mucorales family occurring after the inoculation of fungal spores in disrupted skin. It usually presents as a necrotic eschar but can also present as cellulitis that evolves into a necrotic ulcer. A prompt diagnosis is critical for the effective management of cutaneous mucormycosis. The treatment includes an immediate systemic treatment with amphotericin B and a surgical debridement of the necrotic regions. Given the wide range of presenting symptoms, clinical suspicion for this emergent condition must remain high in immunocompromised and diabetic patients.